About us Leadership History News Clinical Trials Publications Contact us Research & Publications Immunicom is dedicated to uncover, develop, and bring transformational medicines for patients through our breakthrough Immunopheresis® therapies, inventive collaborations, and strategic business development opportunities. Research & Publications September 14, 2021 1st JCA-AACR Precision Cancer Medicine International Conference July 20, 2021 Journal of Clinical Oncology, An American Society of Clinical Oncology Journal June 10, 2021 AACR Journal of Cancer Research Proceedings January 1, 2021 Immunopheresis® Technology Overview February 10, 2020 Journal of Clinical Oncology, An American Society of Clinical Oncology Journal December 31, 2018 Journal of Translational Medicine: “Unleashing Endogenous TNF-alpha as a cancer immunotherapeutic” Immunicom Inc. HEADQUARTERS San Diego, CA RESOURCES Terms of Use Privacy policy GET IN TOUCH Contact us Newsletter Subscription Immunicom’s Immunopheresis® therapy, including the LW-02 blood-filtering immunotherapy device, has not been approved by the US Food and Drug Administration and is an investigational therapy in all of Immunicom’s ongoing clinical research studies. Immunicom’s LW-02 blood-filtering immunotherapy device has been granted European CE Mark Certification for use in adults with advanced, refractory, triple-negative breast cancer in Europe. © 2021 — Immunicom, Inc. All Rights Reserved. We use cookies and similar technologies to enable services and functionality on our site and to understand your interaction with our service. By clicking on accept, you agree to our use of such technologies for marketing and analytics. Cookie settings Accept all